Francois Lilienthal, MD, MBA

Chief Commercial Officer

François is a globally accomplished biopharmaceutical executive and a trained physician with extensive experience in leading end-to-end development and commercialization of innovative medicines, as well as driving significant growth across diversified portfolios through product launches, life cycle management and business development. He successfully led global and US launches of specialty medicines across multiple therapeutic areas at both small biotech and large pharmaceutical companies and built a unique expertise in transforming the commercialization process and partnering with R&D.

Before joining MindMed as Chief Commercial Officer in April 2022, François led Taniken LLC, a consulting firm focused on the development and commercialization of biopharmaceutical products and technologies.

Prior to Taniken, François was a Vice President and General Manager at Merck’s commercial division for 14 years. In his last role, he built and led a new department focused on building the company pipeline and developing the commercial strategy for multiple products across several therapeutic areas, including neurology, psychiatry and pain. He previously drove double-digit growth of the Virology and Liver Diseases global business and oversaw four global launches of innovative brands for the treatment of HIV and chronic hepatitis C.

Before joining Merck, François progressed his commercial career at Tibotec Therapeutics, a US biotech company, and at Janssen Pharmaceuticals and Bristol-Myers Squibb, where he led several product launches and grew their infectious diseases businesses. Francois started his career in R&D at Sanofi with clinical development and medical affairs roles in the US, Europe, and Japan. François is Board Certified in Infectious Diseases in the European Union and graduated with degrees in medicine (MD), statistics (MS) from the University of Paris, and in business (MBA) from the Wharton School at the University of Pennsylvania.

Carol Vallone

Chair of the Board of Directors, Chair of Compensation Committee, Member of Audit/Finance Committee

Andreas Krebs

Vice Chair of the Board of Directors, Chair of Nomination and Governance Committee, Member of Audit/Finance Committee

David Gryska

Board Director, Chair of Audit Committee

Roger Crystal, MD

Board Director, Member of Nomination & Governance Committee, Member of Compensation Committee

Robert Barrow

Chief Executive Officer and Board Director

Suzanne Bruhn, PhD

Board Director, Member of Nomination & Governance Committee, Member of Compensation Committee

Schond Greenway, MBA

Chief Financial Officer

Miri Halperin Wernli, PhD

Executive President

Daniel Karlin, MD, MA

Chief Medical Officer

Mark Sullivan, JD

Chief Legal Officer and Corporate Secretary

Francois Lilienthal, MD, MBA

Chief Commercial Officer

Carrie Liao, CPA

Chief Accounting Officer

Bridget Walton, MS

VP, Global Regulatory Affairs

Robert Malenka, MD, PhD

Chairman of the Scientific Advisory Board, Nancy Friend Pritzker Professor in Psychiatry and Behavioral Sciences at Stanford University

Peter Bergethon, MD

Member, Scientific Advisory Board VP, Head of Quantitative & Clinical Technologies, Biogen, Inc.

Robert Dworkin, PhD

Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry at University of Rochester

Maurizio Fava, MD

Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)

Carole Abel, MBA

VP, Programs and Portfolio Office (PPO)

Peter Mack, PhD

VP, Pharmaceutical Development

Rafael Muniz, MD

VP, Global Medical Affairs

Phong Duong, PharmD

VP, Global Market Access

Maria Oquendo, MD, PhD

Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania, Psychiatrist-in-Chief at the Hospital of the University of Pennsylvania

Matthias Liechti, MD, PhD

Scientific Collaborator & Advisor

Kim PC Kuypers, PhD

Scientific Collaborator & Advisor

Peter Gasser, MD

Clinical Advisor